The North America Biologics Safety Testing Market is projected to exhibit robust growth due to increased demand for biologics, stringent regulatory requirements, and technological advancements in safety testing methodologies. The market size was valued at USD 1,370 Million in 2025 and is expected to reach USD 3,280 Million by 2035, reflecting a CAGR of 8.6% from 2024 to 2035.
The economic impact of tariffs on "North America Biologics Safety Testing Market".
Market Growth Drivers
Rising demand for biologics and biosimilars: The accelerating development and adoption of innovative biologic drugs and biosimilars have amplified the necessity for stringent safety testing to ensure patient safety and comply with regulatory standards. Companies like Thermo Fisher Scientific have expanded their safety testing portfolio to cater to this demand, introducing rapid mycoplasma and virus detection kits to enable faster biologics release, thus fueling the market's growth.
Stringent regulatory requirements and quality standards: Regulatory authorities such as the U.S. FDA and Health Canada have implemented rigorous guidelines for biologics manufacturing, driving companies to adopt advanced safety testing solutions. Lonza Group, for instance, has developed comprehensive testing platforms complying with these standards, helping biopharma firms minimize contamination risks and ensure product quality, which in turn boosts market demand.
Market Trends
Automation and digitalization of safety testing workflows: Technological advancements are driving a shift toward automation and digital integration in biologics safety testing. Companies such as Charles River Laboratories have invested in robotic automation and digital platforms that streamline endotoxin, sterility, and mycoplasma testing, improving accuracy while reducing turnaround time and human error, thus making safety assessment more efficient.
Expansion of contract testing laboratories (CTLs): The growing complexity of biologics and the cost-intensive nature of setting up in-house testing have led biopharma manufacturers to increasingly outsource their safety testing operations. Firms like Eurofins Scientific are expanding their CTL facilities across North America, providing a broad array of testing services and ensuring compliance with evolving regulatory expectations. This outsourcing trend is projected to continue driving market expansion.
Market Opportunity
Emergence of advanced cell and gene therapies: The rising pipeline of cell and gene therapies necessitates specialized safety testing platforms. Companies such as BioReliance (Merck KGaA) are investing in innovation and tailored solutions for these novel therapies, creating new growth opportunities in the market.
Collaborative opportunities with regulatory bodies: Engaging in research collaborations with regulatory agencies allows companies to co-develop robust safety standards. Such initiatives not only accelerate the adoption of new technologies but also expand market reach for solution providers.
North America Biologics Safety Testing Market Revenue (USD Million), 2020-2035
The chart demonstrates a consistent upward trajectory in market revenue for biologics safety testing in North America from 2020 to 2035. Beginning at USD 780 Million in 2020, the market experiences accelerated growth, reaching USD 1,370 Million by 2025. Continued innovation, regulatory drivers, and adoption of new biotherapeutics push the revenue to USD 3,280 Million by 2035. This trend underlines the sector’s resilience and the critical role that safety testing plays in supporting biologics development and commercialization, cementing its status as a vital component of the life sciences value chain.
North America Biologics Safety Testing Market Share by Region, 2025
The pie chart for 2025 market share depicts the United States as the dominant region, accounting for 74% of the North American biologics safety testing market due to its well-established biopharmaceutical industry and advanced regulatory landscape. Canada follows with a 14% share, bolstered by increasing investments in biologics manufacturing. Mexico holds 7%, while the rest is shared among other minor regional markets, each with a 2% and 3% share, respectively. This distribution reflects the concentration of research infrastructure in the U.S. while indicating emerging potential in neighboring countries.
Recent Developments in the North America Biologics Safety Testing Market (Past 6 Months)
In May 2024, Charles River Laboratories launched a next-generation automated mycoplasma detection platform, CRL MycoXpert, which reduces detection time to less than 3 hours for rapid lot release of cell therapy products. This solution aims to help biomanufacturers streamline their workflows, improve accuracy, and comply with evolving regulatory requirements.
In June 2024, Eurofins Scientific announced the expansion of its biologics safety testing operations in Texas, establishing a new laboratory focused on virus clearance and advanced adventitious agent testing. The facility is expected to enhance the company’s service capacity and support the increasing demand for outsourced safety testing by U.S.-based biopharmaceutical firms.
Thermo Fisher Scientific, in April 2024, introduced an integrated digital platform for endotoxin and sterility testing, leveraging artificial intelligence algorithms for automated documentation and result analysis. This innovation significantly accelerates the quality control process for both large- and small-molecule biologics.
Press Releases